Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Myelodysplastic Syndromes 6Leukemia, Myeloid, Acute 5Leukemia 5Lymphoma, Non-Hodgkin 4Primary Immunodeficiency Diseases 3Hematologic Neoplasms 3Cytopenia 3Anemia, Aplastic 3Thalassemia 2Osteopetrosis 2Lymphoma 2Hemoglobinopathies 2Fanconi Anemia 2Anemia, Sickle Cell 2Anemia, Diamond-Blackfan 2Anemia 2Uveal Melanoma 1Thymoma 1Thymic epithelial tumor 1Stomach Neoplasms 1Recurrence 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Myeloma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Graft vs Host Disease 1

Interventions

otelixizumab 1fludarabine phosphate 1fludarabine 1Metoprolol 1Interleukin 1 Receptor Antagonist Protein 1Infliximab 1Etanercept 1Cyclophosphamide 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Cytokine Release Syndrome × AP 1903 reagent × Clear all
NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡